The Problem with Clinical Trials in Duchenne—and What We Can Do About It
cTAP Study Shows Real-World, Natural History Data Comparable to Placebo Data from Clinical Trials in Duchenne Muscular Dystrophy
Results published in peer-reviewed journal Neurology indicate that real-world data (RWD) and natural history data (NHD) could augment or replace placebo controls in DMD clinical trials. Use of RHD and NHD have potential to streamline and accelerate clinical programs targeting new treatments for DMD. CAMBRIDGE, Mass., September 8, 2020 /PRNewswire/ – The Collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, global research coalition in Duchenne muscular dystrophy (DMD), today announced results from the largest ever multi-national,…
Nature Biotechnology: Their Lives in Their Hands
cTAP Publishes Comprehensive Analysis of NSAA
cTAP Partner Wins ISPOR Award on Duchenne Muscular Dystrophy
Moneyball Medicine: Thriving in the new data-driven healthcare market
cTAP to Present Late-breaking Results at the World Muscle Society Congress
cTAP to Present at Annual Biopharmaceutical Conference
Summit Therapeutics Joins cTAP to Support the Development of Potential DMD Treatments
Summit Therapeutics Joins cTAP to Support the Development of Potential DMD Treatments Published September 29, 2017 The newly founded Collaborative Trajectory Analysis Project (cTAP) coalition of stakeholders has invited Summit Therapeutics, a company specialized in the discovery and development of drugs targeting Duchenne muscular dystrophy (DMD), to support the development of new therapeutic products aiming to treat DMD, such as utrophin modulators. cTAP was created to overcome the challenges of developing drugs for diseases characterized…